22nd Congress of the European College of Neuropsychopharmacology

May 25, 2009

The 22nd Congress of the European College of Neuropsychopharmacology (ECNP) will be held from 12-16 September 2009 in Istanbul, Turkey.

More than 6,500 clinical and basic scientists such as psychiatrists, neurologists, psychologists and neuroscience researchers from all over the world will attend the ECNP Congress, which is the largest annual high scientific standard congress on mental disorders and neuropsychopharmacology in Europe. Renowned experts from 25 countries will present the latest achievements and breakthroughs in neuropsychopharmacology and related disciplines in both clinical and preclinical settings, as well as discuss the various aspects of pharmacotherapy of brain disorders and their impact on patients´ quality of life.

The scientific programme will comprise, among others, the following topics:Furthermore, the educational update sessions at the congress will deal with the current knowledge on GABA and biomarkers in neuropsychopharmacology, treatment of insomnia, bipolar disorders and schizophrenia, and the new classification systems ICD-11 and DSM-V.
-end-
For further information about the provisional scientific programme, please visit the ECNP website: www.ecnp.eu

The exciting scientific programme along with the congress site Istanbul, well known for its reputation as cultural and ethnic melting pot, will make the ECNP Congress an outstanding and unforgettable event.

You can register for the 22nd ECNP Congress by submitting your registration form via http://www.ecnp.eu/emc.asp?pageld=1449. Please note that participation in the congress is free of charge for journalists, but requires registration.

Information about press conferences and press releases in the course of the congress will be provided in June 2009.

We hope that this years´ ECNP Congress will attract your interest and that you may join us in our efforts to spread the spirit of scientific adventure and discovery!

We are looking forward to welcoming you to Istanbul.

With kind regards,

Sonja Mak
Press Office ECNP 2009

ECNP Press Office:
Update Europe GmbH.
Tigergasse 3/5
1080 Vienna - Austria
Tel.: +43/1/4055734
Fax: +43/1/4055734-16
E-mail: s.mak@update.europe.at

Over the last years, our understanding of the brain has increased dramatically. This progress is showing great promise of yielding methods to treat and prevent disorders of the brain, ranging from degenerative disorders such as Alzheimer´s or Parkinson´s disease, and psychiatric disorders such as schizophrenia and depression, as well as autism, addictive disorders, and impairments of speech, language, and hearing.

The European College of Neuropsychopharmacology (ECNP), founded in 1987 on the initative of European scientists and clinicians working in neuropsychopharmacology and related disciplines, is a scientific forum that encourages translational research between the neurosciences and clinical practice, thereby translating new knowledge on fundamental disease mechanisms into medical progress and clinical applications (and vice versa). To achieve this objective, ECNP has established a number of activities and programmes in recent years, which facilitate the communication of research results and ideas in the field of neuroscience:

ECNP Congress

The ECNP Congress is the largest annual meeting on psychopharmacology and mental disorders in Europe attended by more than 6,500 clinical and basic scientists such as psychiatrists, neurologists, psychologists and neuroscience researchers from all over the world. The congress' programme is of a very high scientific standard and brings together distinguished scientists and young researchers to discuss the latest achievements and future perspectives in neuropsychopharmacology and related disciplines.

ECNP Regional Meeting, Seminar and Consultation Meeting

The ECNP biennial Regional Meetings (with 200 participants each) and annual Seminars are organised in areas with less opportunity to attend international meetings in order to stimulate the exchange of clinical and basic scientific information within different regions of Europe. At the ECNP Consultation meetings ECNP consults the participating parties, i.e. scientists, regulatory and industry on a specific topic.

ECNP activities for young scientists

As an essential part of stimulating high quality research, ECNP aims to promote and encourage the development of young scientists interested in entering research careers related to mental disorders and their treatment. Therefore ECNP has installed a Research Grant, and offers waived or reduced registration fee and awards such as the ECNP Travel Award and Fellowship Award to facilitate the participation of young scientists at the ECNP Congresses. Furthermore, ECNP organises the annual Workshop on Neuropsycho- pharmacology for Young Scientists in Europe and Targeted Expert Meetings in order to promote the communication of young European scientists with distinguished experts on specific topics.

ECNP School of Neuropsychopharmacology

The aim of the ECNP School is the training of qualified junior clinicians, recommended by the ECNP Advisory Board of National Societies, by teaching them high standard practise in neuropsychopharmacology and involving them in the development of local good practice. Yearly a maximum of 50 young clinicians will be accepted. The first ECNP School of Neuropsychopharmacology will be held from 5 July 2009 in Oxford, UK.

Scientific journal: European Neuropsychopharmacology

The scientific journal of ECNP publishes original findings from basic and clinical research.

Through all its activities, ECNP hopes to increase the scientific understanding of brain and behavioural disorders and to ensure the dissemination of relevant scientific advances in these areas.

For further information about ECNP and its activities please visit the ECNP website: www.ecnp.eu

European College of Neuropsychopharmacology

Related Schizophrenia Articles from Brightsurf:

Schizophrenia: When the thalamus misleads the ear
Scientists at the University of Geneva (UNIGE) and the Synapsy National Centre of Competence in Research (NCCR) have succeeded in linking the onset of auditory hallucinations - one of the most common symptoms of schizophrenia - with the abnormal development of certain substructures of a region deep in the brain called the thalamus.

Unlocking schizophrenia
New research, led by Prof. LIU Bing and Prof. JIANG Tianzi from the Institute of Automation of the Chinese Academy of Sciences and their collaborators have recently developed a novel imaging marker that may help in the personalized medicine of psychiatric disorders.

Researchers discover second type of schizophrenia
In a study of more than 300 patients from three continents, over one third had brains that looked similar to healthy people.

New clues into the genetic origins of schizophrenia
The first genetic analysis of schizophrenia in an ancestral African population, the South African Xhosa, appears in the Jan.

Dietary supplement may help with schizophrenia
A dietary supplement, sarcosine, may help with schizophrenia as part of a holistic approach complementing antipsychotic medication, according to a UCL researcher.

Schizophrenia: Adolescence is the game-changer
Schizophrenia may be related to the deletion syndrome. However, not everyone who has the syndrome necessarily develops psychotic symptoms.

Study suggests overdiagnosis of schizophrenia
In a small study of patients referred to the Johns Hopkins Early Psychosis Intervention Clinic (EPIC), Johns Hopkins Medicine researchers report that about half the people referred to the clinic with a schizophrenia diagnosis didn't actually have schizophrenia.

The ways of wisdom in schizophrenia
Researchers at UC San Diego School of Medicine report that persons with schizophrenia scored lower on a wisdom assessment than non-psychiatric comparison participants, but that there was considerable variability in levels of wisdom, and those with higher scores displayed fewer psychotic symptoms.

Recognizing the uniqueness of different individuals with schizophrenia
Individuals diagnosed with schizophrenia differ greatly from one another. Researchers from Radboud university medical center, along with colleagues from England and Norway, have demonstrated that very few identical brain differences are shared amongst different patients.

Resynchronizing neurons to erase schizophrenia
Today, a decisive step in understanding schizophrenia has been taken.

Read More: Schizophrenia News and Schizophrenia Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.